Institut Pasteur Korea (IPK) was established in 2004 in the cooperation of HQ of Institut Pasteur (France) and the Korea Institute of Science and Technology (KIST). It is a global non-profit research organization conducting researches on infectious diseases including multi-drug resistant bacterial infections and vial pandemic etc. with Korean academia & industries and performing educational activities to the public. In 2017, IPK was chosen as a winner of ‘Bio Core Facility’ project funded by Ministry of Science & ICT (MSIT) for 7 years to build up favorable environments to incubate start-up biotechs in Korea. IPK selected 5 start-up biotechs including Cellatoz Therapeutics, Inc. and has provided them with research spaces & funds and operational supports for 3 years as the first term of the project.
Chonbuk National University has grown into a regional leading university of South-Western Korea with 4 specialized graduate schools, 14 colleges, 100 departments and graduate schools since its foundation in 1948. Chonbuk National Univ. has carried out new drug and cell therapy researches actively with medical science institute under the College of Medicine. Cellatoz Therapeutics, Inc. acquired an original patent on ‘musculoskeletal stem cell and its culture method’ from and entered into an exclusive license agreement on novel cell line with Chonbuk National Univ., and has closely worked together for the joint research & development on MSSC program. .
Ewha Women’s University was founded in 1886 as the first modern women’s education institution of Korea, and has grown into the world’s largest Women’s University by achievements of great successes in various academic sectors with the spirit of challenge and innovation. In particular, the College of Medicine has trained excellent female medical doctors and scientists for over 70 years since its foundation in 1945 and carried out world-class researches in the fields of basic and clinical medicine. Cellatoz Therapeutics, Inc. entered into global exclusive license agreements with Ewha Women’s University on patented technologies to differentiate tonsil-Mesenchymal Stem Cells to Schwann cells and other types of target cells eventually, and has conducted joint research & development of novel regenerative cell therapies.